| Autor: |
Østenstad, B., Pirosa, M. C., Schär, S., Brodtkorb, M., Wahlin, B. E., Hernberg, M., Pedersen, M., Stathis, A., Zander, T., Novak, U., Zenz, T., Fischer, N., Krasniqi, F., Hitz, F., Jjohansson, A., Lofgren, D., Meyer, P., Bjørnevik, A. T., Hayoz, S., Scheibe, B. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p117-119, 3p |
| Abstrakt: |
In total, 192 pts were randomized (98 in arm A rituximab + placebo; 94 in arm B rituximab + ibrutinib) with stratification by rituximab maintenance route, lymphoma grade, follicular lymphoma international prognostic index, and bulky (>=6 cm) disease. The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/14 randomized phase-2 trial (NCT02451111) to evaluate the safety and efficacy of frontline treatment with ibrutinib plus rituximab compared to rituximab plus placebo in adult patients (pts) with advanced follicular lymphoma in need of therapy. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text